Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 262 7123

Website: www.cocrystalpharma.com

Address:

19805 North Creek Parkway, Bothell, United States

elon_musk22 Mar. 17 at 6:52 PM

$COCP the same losers bashing the biotech for years has 2 accounts left but pretends he is short LMFaooo do it - short your life savings I dare you 😭

0 · Reply

elon_musk22 Mar. 17 at 6:46 PM

$COCP my name is dirt bag Doug tshirt down 99% LMFaoooooooooooooooo 😂😭

0 · Reply

elon_musk22 Mar. 17 at 6:45 PM

$COCP $20-25 target soon

0 · Reply

elon_musk22 Mar. 17 at 6:44 PM

$COCP you haven't posted a winner in any of your accounts what about 5000 posts on this shit stock $LCID LMFaoooooo

0 · Reply

elon_musk22 Mar. 17 at 6:43 PM

$COCP you couldn't pay your rent than LMfaooooo loser

0 · Reply

xDOUGx Mar. 17 at 4:45 PM

$COCP I wanted you offer anyone 1000 shares for the best momo bash comment, but then I remember that’s really not much of a prize. We are only in phase 1 trials of this competition … coming soon after funding is approved. But still send we take notes …. Nice

0 · Reply

xDOUGx Mar. 17 at 4:41 PM

$COCP I think my last few posts were winners… if you looking for sound momo bashing advise, follow me 😁 my page teaches you how to bash all his accounts…

0 · Reply

xDOUGx Mar. 17 at 4:38 PM

$COCP oooo touchy touchy. It’s burning isn’t it?

0 · Reply

xDOUGx Mar. 17 at 4:37 PM

$COCP lol, 1000 to 1 RS we will get your $50

0 · Reply

Ultimate1trader Mar. 17 at 2:54 PM

$COCP even $5 until june would be great but there is no indicator

0 · Reply

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Feb 19, 2026, 8:00 AM EST - 26 days ago

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Dec 18, 2025, 8:00 AM EST - 3 months ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 1, 2025, 8:00 AM EST - 3 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Nov 14, 2025, 8:00 AM EST - 4 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 2, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Sep 15, 2025, 4:30 PM EDT - 6 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 6 months ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Jul 10, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

May 29, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 28, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 15, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 2:21 PM EST - 1 year ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 1 year ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 3 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 1, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 5, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 3, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Aug 8, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

elon_musk22 Mar. 17 at 6:52 PM

$COCP the same losers bashing the biotech for years has 2 accounts left but pretends he is short LMFaooo do it - short your life savings I dare you 😭

0 · Reply

elon_musk22 Mar. 17 at 6:46 PM

$COCP my name is dirt bag Doug tshirt down 99% LMFaoooooooooooooooo 😂😭

0 · Reply

elon_musk22 Mar. 17 at 6:45 PM

$COCP $20-25 target soon

0 · Reply

elon_musk22 Mar. 17 at 6:44 PM

$COCP you haven't posted a winner in any of your accounts what about 5000 posts on this shit stock $LCID LMFaoooooo

0 · Reply

elon_musk22 Mar. 17 at 6:43 PM

$COCP you couldn't pay your rent than LMfaooooo loser

0 · Reply

xDOUGx Mar. 17 at 4:45 PM

0 · Reply

xDOUGx Mar. 17 at 4:41 PM

$COCP I think my last few posts were winners… if you looking for sound momo bashing advise, follow me 😁 my page teaches you how to bash all his accounts…

0 · Reply

xDOUGx Mar. 17 at 4:38 PM

$COCP oooo touchy touchy. It’s burning isn’t it?

0 · Reply

xDOUGx Mar. 17 at 4:37 PM

$COCP lol, 1000 to 1 RS we will get your $50

0 · Reply

Ultimate1trader Mar. 17 at 2:54 PM

$COCP even $5 until june would be great but there is no indicator

0 · Reply

resurrect_momo21 Mar. 17 at 1:56 PM

$COCP $50 by June boom boom momo coming

0 · Reply

resurrect_momo21 Mar. 17 at 1:55 PM

$COCP Listen up hater, you sniveling, gutless worm of a small pud crawling out from your mom's basement to spew more about peoples young deaths... You're not a shorter you're a pathetic fraud with a portfolio as empty as your head hiding your non-existent positions because you'd rather jerk off to your own lies than face the truth. Your whole family will die of cancer now since you wish the worst on others! KARMA

0 · Reply

resurrect_momo21 Mar. 17 at 1:52 PM

$COCP 23 yrs on ST broke bully boy who lost all his money can't even find nurse to change his 💩 diaper who need other handles (only broke fucks do you) many of my insane montlhy winners are posted in real time meanwhile you own blackberry from the 90's still LOL loseRrrrr

0 · Reply

xDOUGx Mar. 16 at 11:02 PM

$COCP not to sound cold, but all the board members will pass on before this company produces anything. I’m closer to fixing momo’s issues with his 100 accounts and getting him to move out of his sisters kid’s home than this company is to finishing anything. Insider reports have it that this company is close to finishing phase 1 trials for just wiping their own arse and barta funding is for the 20 extra toilet rolls they needed

1 · Reply

focafoca99 Mar. 14 at 10:42 PM

$COCP board member passing away

0 · Reply

bulmar Mar. 14 at 8:00 PM

$COCP Post winners all the time.. You change fucking handles Momo every other week. 50 otw shut the fuck up. You’ve never been right about this stock. Years of misinformation.

0 · Reply

resurrect_momo21 Mar. 12 at 2:59 PM

$COCP hey diaper boy jai wei I post winners all the time especially in real fucking time you loser you own blackberry from the 90's dip ship punk $50 otw

0 · Reply

resurrect_momo21 Mar. 12 at 2:46 PM

$COCP this poor broke bastard posts from nursing home and shits in his diapers he has been on stock twits so long lost all his money LOL hahahahaahahh loser

0 · Reply

bulmar Mar. 12 at 1:53 PM

$COCP Goddamnit Momo will you ever be right on anything Frost… Nope. Now go cuddle up with the old man.

0 · Reply

resurrect_momo21 Mar. 11 at 10:04 PM

$COCP as a ref $WGS Frost spin off one of the biggest winners ever and I even caught it even late GeneDx $1-160 in 13 months $20 mill to 4 billion view the chart great shit happens all the time in biotech.. its the low life bashers who are morons and mentally and physcially broke and have no life

0 · Reply

resurrect_momo21 Mar. 11 at 7:14 PM

$COCP 16 yr lifetime loser 0 for 7261 ideas never wins read his feed still has never posted a winner in a nursing home now 😭 basheretc 🤡

0 · Reply

bulmar Mar. 11 at 6:50 PM

$COCP If this is going to 50 it better fucking hurry up. When this was 3 bucks Momo/MS101 had this going to 100. Yeah right dummies.

0 · Reply

Market Cap	14.20M
Revenue (ttm)	0.00
Net Income (ttm)	-17.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	75,100
Avg Vol	67,062
Day's Range	N/A - N/A
Shares Out	13.78M
Stochastic %K	91%
Beta	1.18
Analysts	Strong Sell
Price Target	$6.67